Abstract
Background: Molecular biomarkers as C4D in bronchial fluids may contribute to the diagnosis of lung cancer however limited studies were conducted
Aim of the work: to study the role of C4d as a biomarker in the serum and bronchial fluid for lung cancer diagnosis
Patient and Methods: This study is acase control study including (30) participants were diagnosed as lung cancer patients (16)non small cell lung cancer and (14)small cell lung cancer,(15)control group of apparently healthy participants , all patients (group I) were subjected to chest X-ray, chest computed tomography and Flexible bronchoscopy, Forceps biopsies and bronchoalveolar lavage were taken for histopathological , cytological examination and C4D marker measurement also sputum and blood samples were collected for c4d marker measurement, For control group (group II) sputum specimens and blood samples were collected f C4D marker measurement
Results: There were statistically significantly higher C4d level in serum and sputum of lung cancer patients versus control group , There were no statistically significant difference in c4d marker between non small cell and small cell lung cancer , C4D has cut of point with good sensitivity and Specificity in serum and BAL for prediction of lung cancer
Conclusion: complement activation product could be contributed in lung cancer diagnosis as C4d which found elevated in both serum and bronchial fluid of lung cancer patients versus control group and may be considered apredictor of lung cancer with good sensitivity and Specificity in serum and BAL
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1737.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020